Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.M. Pawlotsky.
Molecular diagnosis of viral hepatitis.
Gastroenterology, 122 (2002), pp. 1554-1568
[2.]
A.S.F. Lok, B.J. MacMahon.
Chronic hepatitis B.
Hepatology, 34 (2001), pp. 1225-1241
[3.]
F. Bortolotti, P. Jara, C. Crivellaro, L. Hierro, P. Cadrobbi, E. Frauca, et al.
Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.
J Hepatol, 29 (1998), pp. 184-190
[4.]
P. Jara, F. Bortolotti.
Interferon-K treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children.
J Pediatr Gastroenterol Nutr, 29 (1999), pp. 163-170
[5.]
F. Bortolotti, P. Jara, C. Crivellaro, G.V. Gregorio, A. Vegnente, L. Zancan, et al.
Long term effect of alpha interferon in children with chronic hepatitis B.
Gut, 46 (2000), pp. 715-718
[6.]
J.T. Gerlach, H.M. Diepolder, M.C. Jung, N.H. Gruener, W.W. Schraut, R. Zachoval, et al.
Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C.
Gastroenterology, 117 (1999), pp. 933-941
[7.]
M.F. Yuen, C.K. Hui, C.C. Cheng, C.H. Wu, Y.P. Lai, C.L. Lai.
Long-term follow-up of interferon alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Hepatology, 34 (2001), pp. 139-145
[8.]
M.M. Jonas, D.A. Kelly, J. Mizerski, I.B. Badía, J.A. Areias, K.B. Schwarz, et al.
Clinical trial of lamivudine in children with chronic hepatitis B.
N Engl J Med, 346 (2002), pp. 1706-1713
[9.]
M.H. Chang.
Hepatitis B vaccination and control of hepatitis B-related liver disease.
J Pediatr Gastroenterol Nutr, 31 (2000), pp. 112-117
[10.]
Y.H. Ni, M.H. Chang, L.M. Huang, H.L. Chen, H.Y. Hsu, T.Y. Chiu, et al.
Hepatitis B virus infection in children and adolescent in a hyperendemic area: 15 years after mass Hepatitis B vaccination.
Ann Intern Med, 135 (2001), pp. 796-800
[11.]
European Consensus Group on Hepatitis B Immunity.
Are booster immunisations needed for lifelong hepatitis B immunity?.
Lancet, 355 (2000), pp. 561-565
[12.]
C. Brechot.
Hepatitis C virus: molecular biology and genetic variability.
Dig Dis Sci, 41 (1996), pp. 6-21
[13.]
S. Deuffic, L. Buffat, T. Poynard, A.J. Valleron.
Modeling the hepatitis C virus epidemic in France.
Hepatology, 29 (1999), pp. 1596-1601
[14.]
L.T. Yeung, S.M. King, E.A. Roberts.
Mother-to-infant transmission of hepatitis C virus.
Hepatology, 34 (2001), pp. 223-229
[15.]
M. Resti, C. Azzari, L. Galli, G. Zuin, R. Giacchino, F. Bortolotti, et al.
Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs.
J Infect Dis, 185 (2002), pp. 567-572
[16.]
N. Boyer, P. Marcellin.
Pathogenesis, diagnosis and management of hepatitis C.
J Hepatol, 32 (2000), pp. 98-112
[17.]
M. Guido, M. Rugge, P. Jara, L. Hierro, R. Giacchino, J. Larrauri, et al.
Chronic hepatitis C virus infection in childhood: the pathological and clinical spectrum.
Gastroenterology, 115 (1998), pp. 1525-1529
[18.]
P. Jara, L. Hierro, M.C. Díaz, F. Frauca, A. De la Vega, C. Camarena, et al.
Hepatitis C asociada a anti LKM + en niños. Estudio multicéntrico.
Gastroenterología Hepatología, 25 (2002), pp. 93
[19.]
K.R. Jacobson, K. Murray, A. Zellos, K.B. Schwarz.
An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.
J Pediatr Gastroenterol Nutr, 34 (2002), pp. 52-58
[20.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis Cvirus. International Hepatitis Interventional Therapy Group.
Lancet, 352 (1998), pp. 1426-1432
[21.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Schiffman, W.H. Lee, V.K. Rustgi, et al.
Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
N Engl J Med, 339 (1998), pp. 1485-1492
[22.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Schiffman, R. Reindollar, et al.
Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. A randomized trial.
Lancet, 358 (2001), pp. 958-965
[23.]
B. Christennson, T. Wiebe, A. Akesson, A. Widell.
Interferon- K and ribavirin treatment of hepatitic C in children with malignancy in remission.
Clin Infect Dis, 30 (2000), pp. 585-586
[24.]
H. Lackner, A. Moser, J. Deutsch, H.H. Kessler, M. Benesch, R. Kerbl, et al.
Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy.
Pediatrics, 106 (2000), pp. E53
[25.]
D.A. Kelly, S.K. Bunn, D. Apelian, A. Baczkowski, S. Gupta, M. Laughlin, M. Cohard, et al.
Safety, efficacy and pharmacokinetics of interferon alpha-2b plus ribavirin in children with chronic hepatitis C.
Hepatology, 34 (2001), pp. 342A
[26.]
S. Wirth, T. Lang, S. Gehring, P. Gerner.
Recombinant alphainterferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.
Hepatology, 36 (2002), pp. 1280-1284
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados